Products Introduction

Product Name: Dapagliflozin Raw Powder API Product Purity: ≥99.0% CAS No : 960404-48-2 Detection Method: HPLC Molecular Formula: C₂₁H₂₅ClO₆ Molecular Weight: 408.87 g/mol EINECS No : 811-335-4 Product Appearance: White to off-white crystalline powder Product Packaging: 1KG in aluminum foil bag; 25KG/drum（Customizable） Product Storage: Store at -20°C (powder, 3 years), -80°C for stock solutions (1 year) Shelf Life: 24 months   Declaration of Use: This product is intended for industrial use or scientific research only.

Products Description

Dapagliflozin is a high-purity Active Pharmaceutical Ingredient (API) belonging to the gliflozin class. It is a white to off-white crystalline powder characterized by its high selectivity for the SGLT2 transporter. Chemically, it is a C-glycosyl compound consisting of a glucose sugar unit linked to an ethoxybenzyl-chlorobenzene moiety. As an API, it is produced under strict quality control standards (HPLC≥99.0%) to ensure suitability for oral solid dosage formulation.

• High Purity & Stability: With a purity specification of ≥99.0%, the material minimizes impurities that could affect the safety or efficacy of the final drug product. The 24-month shelf life ensures long-term inventory stability when stored correctly.

• Insulin-Independent Mechanism: Unlike many other antidiabetic agents, it works via the kidneys, making it effective for patients with varying degrees of insulin resistance.

• Crystalline Consistency: The "white to off-white crystalline powder" form is optimized for consistent flow properties and solubility during the tableting or encapsulation process.

• Established Regulatory Profile: Dapagliflozin is a globally recognized molecule with extensive clinical data supporting its multi-organ benefits (heart, kidney, and metabolic health).

This API is intended for use in the pharmaceutical industry for the manufacturing of finished dosage forms:

• Monotherapy: Used as a primary ingredient in tablets (commonly 5mg or 10mg) for the management of Type 2 Diabetes Mellitus.

• Combination Therapies: Often formulated alongside other glucose-lowering agents, such as Metformin or Saxagliptin, to provide synergetic glycemic control.

• Therapeutic Indications:

• Glycemic Control: Improving blood sugar levels in adults with type 2 diabetes.

• Heart Failure (HFrEF): Reducing the risk of cardiovascular death and hospitalization.

• Chronic Kidney Disease (CKD): Reducing the risk of sustained eGFR decline and end-stage kidney disease.

Safety Warning

This product is a chemical raw material intended for professional laboratory research or pharmaceutical manufacturing only. It is not for direct human consumption in its raw powder form. Handling should be conducted in a controlled environment by trained professionals.

Packaging